{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-113576","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.348291+00:00","generated_at":"2026-06-09T00:43:11.185007+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bicycle Therapeutics Q3 net loss $49.9M; FDA aligns on BT8009 Phase 2/3 trial for bladder cancer","bullets":["Net loss $49.9M ($1.26/share) vs $28.3M ($0.96/share) in Q3 2022; R&D expenses rose to $39.9M.","Cash $572.1M as of Sep 30, 2023, up from $339.2M at Dec 31, 2022, including $215.1M net from July offering.","FDA aligned on Phase 2/3 registrational trial (Duravelo-2) for BT8009 in metastatic bladder cancer; starts Q1 2024.","BT8009 selected for FDA's CMC Development and Readiness Pilot (CDRP) program to expedite manufacturing.","Company plans R&D Day on Dec 14, 2023, to provide updates on BT8009, BT5528, and BT7480."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-113576","json":"https://secwatch.observer/filing/0001104659-23-113576.json","markdown":"https://secwatch.observer/filing/0001104659-23-113576.md","text":"https://secwatch.observer/filing/0001104659-23-113576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923113576/0001104659-23-113576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923113576/tm2329595d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:43:11.185007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66d9f5a48243d980ca88a75013297b1cf8e57e6c","claim":"BICYCLE THERAPEUTICS PLC reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended September 30, 2023 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923113576/0001104659-23-113576-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}